AstraZeneca completes sale of US rights for nasal spray
AstraZeneca has completed the sale of rights to its nasal spray outside of the US with Swiss pharmaceutical Cilag for $330m.
AstraZeneca
10,594.00p
17:15 03/01/25
-0.34%
-36.00p
Dow Jones I.A.
42,732.13
04:30 15/10/20
n/a
n/a
FTSE 100
8,223.98
16:59 03/01/25
n/a
n/a
FTSE 350
4,534.15
16:54 03/01/25
n/a
n/a
FTSE All-Share
4,490.88
17:14 03/01/25
n/a
n/a
Johnson & Johnson
$144.19
10:59 03/01/25
0.12%
$0.17
Pharmaceuticals & Biotechnology
20,224.34
16:54 03/01/25
-0.60%
-121.88
The FTSE 100 company sold the rights for Rhinocort Aqua, a nasal spray to treat allergic and nonallergic rhinitis and polyps, for use outside of the US to a subsidiary of Johnson & Johnson.
It received payment of £330m, which will be booked in the fourth quarter of 2016, and will now not have a significant ongoing interest in Rhinocort Aqua.